Interactions entre les traitements du diabète et le microbiote intestinal : état des connaissances et perspectives

Aron-Wisnewsky, Judith;Lefevre, Camille;Bindels, Laure
(2022) Médecine des Maladies Métaboliques — Vol. 16, n° 2, p. 148-159 (2022)

Files

2022_Aron_Wisnewksy_Med_Maladies_Metab_Ab.pdf
  • Open Access
  • Adobe PDF
  • 355.2 KB
Download

Details

Authors
  • Aron-Wisnewsky, Judith
    Author
  • Lefevre, Camilleorcid-logoUCLouvain
    Author
  • Bindels, LaureUCLouvain
    Author
Abstract
(en) [Interplay between glucose lowering drugs and the intestinal gut microbiota: What is currently known and future directions] Type 2 diabetes (T2D) management starts with modifications of food patterns and dietary intake with an increase in physical activity, two parameters known to differentially modulate the intestinal gut microbiota. As a second step, if the glycemic target is not achieved, metformin is the first line of treatment. If hyperglycemia persists, several other glucose lowering drugs can be added. To date, the literature has accumulated evidence from murine models as well as from human studies that these drugs modulate the intestinal gut microbiota. Furthermore, for patients with T2D and severe obesity, bariatric surgery is a new therapeutic option that improves glycemic control and modifies the composition of the intestinal microbiota. A few pilot studies have even displayed some microbial signatures of T2D remission after bariatric surgery. Finally, several new therapeutic approaches (next generation probiotics, fecal microbiota transfer), tested in patients with obesity and the metabolic syndrome, improve insulin resistance. These treatments are new therapeutic perspectives that should now be tested in patients with T2D. This review details how all the above treatment options modulate the intestinal gut microbiota and their links with improved glucose control.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Aron-Wisnewsky, J., Lefevre, C., & Bindels, L. (2022). Interactions entre les traitements du diabète et le microbiote intestinal : état des connaissances et perspectives. Médecine des Maladies Métaboliques, 16(2), 148-159. https://doi.org/10.1016/j.mmm.2022.01.004 (Original work published 2022)